Clinical Trials in Salamanca, Spain
2 recruiting
Showing 1–20 of 22 trials
Recruiting
Phase 3
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
AstraZeneca675 enrolled281 locationsNCT06357533
Recruiting
Phase 3
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Breast NeoplasmsTriple Negative Breast NeoplasmsHR Low-Positive/HER2-Negative Breast Neoplasms
Merck Sharp & Dohme LLC2,400 enrolled234 locationsNCT06966700
Recruiting
Phase 3
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Chronic Lymphocytic LeukemiaMantle Cell LymphomaFollicular Lymphoma+1 more
Janssen Research & Development, LLC700 enrolled174 locationsNCT01804686
Recruiting
Phase 3
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Breast NeoplasmsNeoplasm Metastasis
Eli Lilly and Company920 enrolled303 locationsNCT07174336
Recruiting
OSIREAL - Osimertinib RWE on EGFRm NSCLC in Spain
Non-small Cell Lung Cancer
AstraZeneca500 enrolled25 locationsNCT06068049
Recruiting
Phase 2
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
Breast Cancer
Hoffmann-La Roche60 enrolled25 locationsNCT07054190
Recruiting
Phase 3
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
AstraZeneca4,300 enrolled727 locationsNCT05774951
Recruiting
Not Applicable
Diagnostic HER2DX-guided Treatment for Patients wIth Early-stage HER2-positive Breast Cancer
HER2-positive Breast Cancer
Fundacio Clinic Barcelona304 enrolled29 locationsNCT06446882
Recruiting
DESTINY Breast Respond HER2-low Europe
Metastatic Breast CancerUnresectable Breast CancerHER2-low Expressing Breast Cancer
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company1,155 enrolled211 locationsNCT05945732
Recruiting
Phase 2
PALACE: Cemiplimab Trial According to ctDNA Levels
Fundación GECP63 enrolled20 locationsNCT06917573
Recruiting
Phase 2
Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC)
Fundación GECP97 enrolled21 locationsNCT07153445
Recruiting
An Ophthalmic Safety Study in Patients With Breast Cancer
Ophthalmic Safety in Patients With Breast Cancer
AstraZeneca160 enrolled75 locationsNCT06767462
Recruiting
Phase 3
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
AstraZeneca5,500 enrolled794 locationsNCT05952557
Recruiting
Not Applicable
Effect of Cryotherapy in the Prevention of Madarosis Produced by Chemotherapy in Breast Cancer Patients
Breast NeoplasmsAlopeciaMadarosis+5 more
University of Salamanca120 enrolled2 locationsNCT06955702
Recruiting
Long-Term Follow-up Study of Early Stage Breast Cancer Patients Included in GEICAM Studies
Invasive Breast Cancer Early Stages
Spanish Breast Cancer Research Group8,000 enrolled73 locationsNCT03390894
Recruiting
Phase 1Phase 2
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Endometrial CancerAdvanced Solid TumorDiffuse Large B Cell Lymphoma+5 more
Novartis Pharmaceuticals275 enrolled60 locationsNCT04104776
Recruiting
Phase 2
DUMAS: Neo-Adjuvant Immunotherapy for Pancoast Tumors
NSCLCPancoast Tumor
Fundación GECP22 enrolled29 locationsNCT05684276
Recruiting
Phase 3
Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.
Lung Diseases
Fundación GECP129 enrolled30 locationsNCT06431633
Recruiting
Not Applicable
Cardiovascular Prevention Strategies in Elderly Patients With Cancer (CARTIER Clinical Trial)
CardiotoxicityCancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma)Elderly+1 more
Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León514 enrolled14 locationsNCT03711110
Recruiting
Phase 2
Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer
Breast Cancer Stage II
SOLTI Breast Cancer Research Group1,100 enrolled51 locationsNCT05296746